Home › Funds › Siren, L.L.C. › RYTM
Siren, L.L.C. position in RYTM
Rhythm Pharmaceuticals, Inc. · Health Care
Siren, L.L.C. reported holding 1,086,275 shares of RYTM (Rhythm Pharmaceuticals, Inc.) in its Q3 2026 13F filing — a position valued at US$103.4M, representing 2.46% of its reported portfolio and ranking #10 among its reported holdings. Siren, L.L.C. has disclosed RYTM holdings in 7 of the last 7 reported quarters, going back to Q1 2025.
Last updated: 2026-11-12 · Source: SEC EDGAR Form 13F-HR
How Siren, L.L.C.'s RYTM position evolved
Siren, L.L.C. first disclosed a stake in RYTM in Q1 2025 at 277,533 shares (US$14.7M). The position peaked in Q2 2026 at 1,136,275 shares, worth US$126.2M. Across 7 filings, Siren, L.L.C. increased the stake 4 time(s), trimmed it 1 time(s) and left it unchanged 1 time(s). The most recent filing (Q3 2026) shows 1,086,275 shares valued at US$103.4M — a reduction of -50,000 shares quarter over quarter.. Notable position changes include a 48% increase in Q2 2025 (shares rose 60% over the following quarter), a 45% increase in Q1 2026 (shares rose 28% over the following quarter), a 57% increase in Q2 2026 (shares fell 14% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q1 2025 | 277.53K | $14.70M | New |
| Q2 2025 | 409.74K | $25.89M | Add |
| Q3 2025 | 499.98K | $50.49M | Add |
| Q4 2025 | 499.98K | $53.52M | Hold |
| Q1 2026 | 725.51K | $63.10M | Add |
| Q2 2026 | 1.14M | $126.16M | Add |
| Q3 2026 | 1.09M | $103.43M | Reduce |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About RYTM and 13F data
RYTM (Rhythm Pharmaceuticals, Inc.) is a Health Care company. 50 other funds we track also report a position in RYTM — the largest reported positions include RA CAPITAL MANAGEMENT, L.P. (US$740.2M), BAKER BROS. ADVISORS LP (US$622.3M), PERCEPTIVE ADVISORS LLC (US$287.2M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding RYTM
- RA CAPITAL MANAGEMENT, L.P. 6.67M sh · $740.22M · Q2 2026
- BAKER BROS. ADVISORS LP 5.60M sh · $622.27M · Q2 2026
- PERCEPTIVE ADVISORS LLC 2.59M sh · $287.16M · Q2 2026
- WESTFIELD CAPITAL MANAGEMENT CO LP 2.21M sh · $245.22M · Q2 2026
- Polar Capital Holdings Plc 1.66M sh · $184.71M · Q2 2026
- Checkpoint Capital L.P. 1.19M sh · $131.68M · Q2 2026
- Rock Springs Capital Management LP 692.60K sh · $76.90M · Q2 2026
- Integral Health Asset Management, LLC 550.00K sh · $61.07M · Q2 2026
- Sofinnova Investments, Inc. 408.03K sh · $45.30M · Q2 2026
- BRAIDWELL LP 381.13K sh · $42.32M · Q2 2026
FAQ
How long has Siren, L.L.C. held RYTM?
Siren, L.L.C. has disclosed RYTM holdings in 7 of the last 7 reported quarters, going back to Q1 2025.
What is Siren, L.L.C.'s current position in RYTM?
As of Q3 2026, Siren, L.L.C. holds 1.09M shares of RYTM (Rhythm Pharmaceuticals, Inc.), valued at $103.43M, representing 2.46% of its reported portfolio and ranking #10.
Has Siren, L.L.C. been buying or selling RYTM?
In the latest 13F filing (Q3 2026), Siren, L.L.C. reduced its position in RYTM. The position peaked in Q2 2026 at 1.14M shares.
Which other funds hold RYTM?
Other major institutional holders of RYTM include RA CAPITAL MANAGEMENT, L.P., BAKER BROS. ADVISORS LP, PERCEPTIVE ADVISORS LLC, among 50 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.